Dermaliq Therapeutics, Inc., is a private pharmaceutical company with a therapeutic focus on dermatology, founded in 2021 through a spin-off from Novaliq GmbH.
Total raised: $15M
Investors 1
| Date | Name | Website |
| 03.03.2022 | 3E Biovent... | 3ebiovc.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.01.2022 | Series A | $15M | - |
Mentions in press and media 3
| Date | Title | Description |
| 18.01.2022 | Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into the Clinics | - |
| 18.01.2022 | Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials | WILMINGTON, Del., Jan. 18, 2022 /PRNewswire/ -- Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establishment of Dermaliq Therapeutics, Inc (Dermaliq), a newly formed Delaware-based pha... |
| 18.01.2022 | Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials | - Dermaliq Therapeutics, Inc. is an independent private pharmaceutical company emerged from Novaliq - Spin-off to unlock value in the space of medical dermatology by using Novaliq's transformative technology outside eye care - 3E Bioventure... |